GlassScriptPhysician profile
Tamera Jo Wolf
NPI 1356342232
$215,476.41
in general payments reported to CMS, 2019-2025
33 companies · $56K in 2025
The $56K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13K · 2022: $19K · 2023: $56K · 2024: $71K · 2025: $56K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $141K · Travel and Lodging: $17K · Food and Beverage: $15K · Honoraria: $7,150 · Consulting Fee: $3,243 · Education: $495.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $141,457.12 |
| Travel and Lodging | $17,008.04 |
| Food and Beverage | $14,556.68 |
| Honoraria | $7,150.00 |
| Consulting Fee | $3,243.00 |
| Education | $495.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $92,480.39 | 2021-2025 | Tremfya |
| Lilly USA, LLC | $39,984.60 | 2021-2025 | Ebglyss, Taltz, Olumiant |
| Dermavant Sciences, INC. | $32,184.31 | 2022-2024 | Vtama |
| Janssen Scientific Affairs, LLC | $26,749.89 | 2021-2025 | Tremfya |
| Organon LLC | $9,362.81 | 2024-2025 | Vtama |
| Abbvie INC. | $2,844.98 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $2,005.64 | 2022-2025 | Sotyktu |
| Leo Pharma INC. | $1,373.70 | 2021-2025 | Adbry, Anzupgo |
| Novartis Pharmaceuticals Corporation | $1,030.35 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $996.73 | 2021-2025 | Dupixent, Libtayo |
| Ucb, INC. | $755.17 | 2021-2025 | Bimzelx, Cimzia |
| Sun Pharmaceutical Industries INC. | $733.19 | 2021-2025 | Ilumya, Winlevi, Absorica Ld |
| Galderma Laboratories, L.P. | $681.81 | 2021-2024 | Epsolay |
| Journey Medical Corporation | $668.29 | 2021-2025 | |
| Mayne Pharma Commercial LLC | $627.50 | 2021-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $597.27 | 2021-2025 | Otezla, Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $531.36 | 2021-2025 | Cabtreo, Arazlo, Jublia |
| Pfizer INC. | $400.92 | 2021-2023 | |
| Arcutis Biotherapeutics, INC. | $345.01 | 2023-2025 | Zoryve |
| Stemline Therapeutics INC. | $223.88 | 2021 | |
| Genzyme Corporation | $212.30 | 2021-2025 | |
| Almirall LLC | $175.97 | 2021-2025 | Seysara, Klisyri |
| Organogenesis INC. | $144.55 | 2024 | |
| Incyte Corporation | $135.75 | 2023 | Opzelura |
| Blueprint Medicines Corporation | $64.58 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.91 | 2023 | Cyltezo |
| Hydrofera LLC | $20.89 | 2025 | Hydrofera Blue |
| Springworks Therapeutics, INC. | $20.02 | 2025 | Gomekli |
| Kerecis Limited | $18.75 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Vyne Pharmaceuticals INC. | $18.20 | 2021 | |
| Mallinckrodt Hospital Products INC. | $17.71 | 2025 | Acthar |
| Kyowa Kirin, INC. | $16.82 | 2023 | Poteligeo |
| Biofrontera INC. | $11.16 | 2024 | Ameluz, Xepi, Bf-Rhodoled |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamera Wolf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.